Cancer Immunotherapy

被引：5
作者：
Bergman, Philip J. [1 ,2 ]
机构：
[1] BrightHeart Vet Ctr, Armonk, NY 10504 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
来源：
VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE | 2010年 / 40卷 / 03期
关键词：
Cancer; Vaccine; Immunotherapy; Tumor; ENCAPSULATED MURAMYL TRIPEPTIDE; REGULATORY T-CELLS; SPONTANEOUS CANINE MELANOMA; COLONY-STIMULATING FACTOR; BIOLOGICAL RESPONSE MODIFIERS; RECOMBINANT FELINE INTERFERON; MEDIATED IMMUNE-RESPONSES; IMIQUIMOD 5-PERCENT CREAM; BACILLUS-CALMETTE-GUERIN; SOFT-TISSUE SARCOMA;
D O I：
10.1016/j.cvsm.2010.01.002
中图分类号：
S85 [动物医学（兽医学）];
学科分类号：
0906 ;
摘要：
The veterinary oncology profession is uniquely able to contribute to the many advances that are imminent in immunotherapy. However, what works in a mouse will often not reflect the outcome in human patients with cancer. Therefore, comparative immunotherapy studies using veterinary patients may be better able to bridge murine and human studies. Many cancers in dogs and cats seem to be stronger models for their counterpart human tumors than presently available murine model systems. This author looks forward to the time when immunotherapy plays a significant role in the treatment and/or prevention of cancer in human and veterinary patients.
引用
收藏
页码：507 / +
页数：13
相关论文
共 100 条
[1]   Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model [J].
Akhtar, N ;
Padilla, ML ;
Dickerson, EB ;
Steinberg, H ;
Breen, M ;
Auerbach, R ;
Helfand, SC .
NEOPLASIA, 2004, 6 (02) :106-116
[2]   Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma [J].
Alexander, AN ;
Huelsmeyer, MK ;
Mitzey, A ;
Dubielzig, RR ;
Kurzman, ID ;
MacEwen, EG ;
Vail, DM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (04) :433-442
[3]   Oncolytic gene therapy for canine cancers: teaching old dog viruses new tricks [J].
Arendt, M. ;
Nasir, L. ;
Morgan, I. M. .
VETERINARY AND COMPARATIVE ONCOLOGY, 2009, 7 (03) :153-161
[4]   Cancer immunotherapy [J].
Baxevanis, Constantin N. ;
Perez, Sonia A. ;
Papamichail, Michael .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2009, 46 (04) :167-189
[5]  
Bergman P.J., 2008, Cancer Therapy, V6, P817
[6]   Anticancer Vaccines [J].
Bergman, Philip J. .
VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE, 2007, 37 (06) :1111-+
[7]   Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center [J].
Bergman, PJ ;
Camps-Palau, MA ;
McKnight, JA ;
Leibman, NF ;
Craft, DM ;
Leung, C ;
Liao, J ;
Riviere, I ;
Sadelain, M ;
Hohenhaus, AE ;
Gregor, P ;
Houghton, AN ;
Perales, MA ;
Wolchok, JD .
VACCINE, 2006, 24 (21) :4582-4585
[8]  
Bergman PJ, 2003, CLIN CANCER RES, V9, P1284
[9]  
Bergman PJ, 2001, VET ONCOLOGY SECRETS, P79
[10]   Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer [J].
Biller, B. J. ;
Elmslie, R. E. ;
Burnett, R. C. ;
Avery, A. C. ;
Dow, S. W. .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2007, 116 (1-2) :69-78
12345678910